Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, canakinumab (Ilaris®) cannot be endorsed for use within NHS Wales for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in children aged 2 to < 4 years. |
||
|
||
Medicine details |
||
| Medicine name | canakinumab (Ilaris®) | |
| Formulation | 150 mg powder for solution for injection | |
| Reference number | 1208 | |
| Indication | Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in children aged 2 to < 4 years |
|
| Company | Novartis Pharmaceuticals UK Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 29/07/2013 | |